<div id="readability-page-1"><div>RNS Number : 5395Q Morgan Stanley &amp; Co. Int'l plc 27 January 2026 FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the &#34;Code&#34;)1. KEY INFORMATION<div><table><tbody><tr><td>(a) Name of exempt principal trader:</td><td>Morgan Stanley &amp; Co. International plc</td></tr><tr><td>(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree</td><td>Oxford Biomedica plc</td></tr><tr><td>(c) Name of the party to the offer with which exempt principal trader is connected:</td><td>EQT Fund Management S.a.r.l.</td></tr><tr><td>(d) Date dealing undertaken:</td><td>26 January 2026</td></tr><tr><td>(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td><td>N/A</td></tr></tbody></table></div>2. DEALINGS BY THE EXEMPT PRINCIPAL TRADERWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and sales<div><table><tbody><tr><td>Class of relevant security</td><td>Purchases/ sales</td><td>Total number of securities</td><td>Highest price per unit paid/received</td><td>Lowest price per unit paid/received</td></tr><tr><td>50p ordinary</td><td>SALES</td><td>2</td><td>11.8757 USD</td><td>11.8757 USD</td></tr><tr><td>50p ordinary</td><td>PURCHASES</td><td>23,798</td><td>8.6926 GBP</td><td>8.6045 GBP</td></tr><tr><td>50p ordinary</td><td>SALES</td><td>204,689</td><td>8.7000 GBP</td><td>8.6000 GBP</td></tr></tbody></table></div>(b) Cash-settled derivative transactions<div><table><tbody><tr><td>Class of relevant security</td><td>Product descriptione.g. CFD</td><td>Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position</td><td>Number of reference securities</td><td>Price per unit</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>5,862</td><td>8.6355 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>317</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>15,168</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>156,862</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>1,402</td><td>8.6404 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>990</td><td>8.6453 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>96</td><td>8.6473 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a long position</td><td>2</td><td>8.6650 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a short position</td><td>469</td><td>8.6382 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a short position</td><td>1,200</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>increasing a short position</td><td>1,891</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>14</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>167</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>317</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>459</td><td>8.6489 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>222</td><td>8.6510 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>57</td><td>8.6793 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a long position</td><td>623</td><td>8.6882 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>20</td><td>8.6100 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>247</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>206</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>4</td><td>8.6400 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>2,256</td><td>8.6454 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>1</td><td>8.6500 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>1,441</td><td>8.6583 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>4</td><td>8.6600 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>25</td><td>8.6688 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>500</td><td>8.6804 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>404</td><td>8.6854 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>211</td><td>8.6855 GBP</td></tr><tr><td>50p ordinary</td><td>CFD</td><td>reducing a short position</td><td>69</td><td>8.7000 GBP</td></tr></tbody></table></div>(c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varying<div><table><tbody><tr><td>Class of relevant security</td><td>N/A</td></tr><tr><td>Product description e.g. call option</td><td>N/A</td></tr><tr><td>Writing, purchasing, selling, varying etc.</td><td>N/A</td></tr><tr><td>Number of securities to which option relates</td><td>N/A</td></tr><tr><td>Exercise price per unit</td><td>N/A</td></tr><tr><td>Typee.g. American, European etc.</td><td>N/A</td></tr><tr><td>Expiry date</td><td>N/A</td></tr><tr><td>Option money paid/ received per unit</td><td>N/A</td></tr></tbody></table></div>(ii) Exercise<div><table><tbody><tr><td>Class of relevant security</td><td>N/A</td></tr><tr><td>Product descriptione.g. call option</td><td>N/A</td></tr><tr><td>Exercising/ exercised against</td><td>N/A</td></tr><tr><td>Number of securities</td><td>N/A</td></tr><tr><td>Exercise price per unit</td><td>N/A</td></tr></tbody></table></div>(d) Other dealings (including subscribing for new securities)<div><table><tbody><tr><td>Class of relevant security</td><td>N/A</td></tr><tr><td>Nature of dealinge.g. subscription, conversion</td><td>N/A</td></tr><tr><td>Details</td><td>N/A</td></tr><tr><td>Price per unit (if applicable)</td><td>N/A</td></tr></tbody></table></div>3. OTHER INFORMATION(a) Indemnity and other dealing arrangements<ul><li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li><li>NONE</li></ul>(b) Agreements, arrangements or understandings relating to options or derivatives<ul><li>Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li><li>NONE</li></ul><div><table><tbody><tr><td>Date of disclosure:</td><td>27 January 2026</td></tr><tr><td>Contact name:</td><td>Claire Gordon</td></tr><tr><td>Telephone number:</td><td>+44 141 245-8893</td></tr></tbody></table></div>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0) 20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END FERPPUUPGUPQUBM</div></div>

Morgan Stanley & Co. International plc disclosed its dealings in Oxford Biomedica plc's securities as per Rule 8.5 of the Takeover Code. On January 26, 2026, the firm reported sales of 204,689 shares at prices ranging from £8.60 to £8.70 and purchases of 23,798 shares at prices between £8.60 and £8.69. Additionally, it increased long positions in cash-settled derivatives and reduced short positions in various transactions. The disclosure was made on January 27, 2026, by Claire Gordon.

REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI)-Oxford Biomedica plc